返回首页
  • [背景] 肿瘤介入与免疫:背景分析 日期:2021-03-17 06:17:28 点击:68 好评:0

    介入放射学/肿瘤免疫学新焦点 IR/IO New Focus 我们打盹......我们输了!!! ! Ipilimumab: $1 billion sales 2015; Nivolimumab: $2 billion /year What is IO Immunotherapy? IRs can potentiate local-regional systemic synergy What systemic effec...

  • [冷冻消融] 冷冻消融与免疫 日期:2021-03-07 18:55:31 点击:107 好评:0

    Local treatments: Surgery, Radiotherapy Systemic treatments: Chemotherapy, Targeted therapy, Immunotherapy Passive immunotherapy - Killer T cells (NK, LAK, TIL, CTL) - Antibodies, toxin conjugates Active immunization / vaccines - Tumor ant...

  • [肿瘤介入与免疫未来] 肿瘤介入与免疫未来 日期:2021-02-07 21:00:39 点击:188 好评:0

    Future IO + Immunotherapy Trials in HCC Greten: Clin Cancer Res 2013;19:6678-6685 Future Directions 1, Combination IO Immunomodulator Rx Anti-CTLA4 + Anti PD1/PDL1 2. Timing / sequence? 3. Local HA Treme? 4. +/- Sorafenib logical: impacts...

  • [癌细胞被杀死] 免疫循环与介入治疗:杀死癌细胞 日期:2021-01-30 21:51:47 点击:191 好评:0

    1...

  • [增强肿瘤诱导免疫文献] 射频消融术诱导抗原呈递细胞浸润,增强肿瘤诱导免疫 日期:2021-01-30 16:11:02 点击:126 好评:0

    引自苏大二院介入治疗科文献复习 射频消融术诱导抗原呈递细胞浸润,增强肿瘤诱导免疫 评估次全射频(RF)消融对小鼠肿瘤模型中肿瘤特异性免疫应答的影响,并探讨肿瘤内树突状细胞(ITDCs)在其中的作用。 材料和方法: 动物模型工作根据批准的方案进行,并符...

  • [癌抗原呈递] 肿瘤介入与免疫:抗原呈递 日期:2021-01-30 16:03:58 点击:98 好评:0

    射频消融术诱导抗原呈递细胞浸润,增强肿瘤诱导免疫 评估次全射频(RF)消融对小鼠肿瘤模型中肿瘤特异性免疫应答的影响,并探讨肿瘤内树突状细胞(ITDCs)在其中的作用。 材料和方法: 动物模型工作根据批准的方案进行,并符合国家癌症研究所动物护理和使用...

  • [抗原释放] 癌免疫循环与介入治疗 日期:2021-01-30 15:57:51 点击:66 好评:0

    消融几何:边缘处的亚致死生物学是一个动态的、尚且未知的过程 Ablation Geometry: Sublethal Biology at Edge is a Dynamic Poorly Understood Process RFA/MWA Cryoablation 消融模式及免疫机制:Ablation Modalities Immune Mechanisms: 冷冻、油炸或撼动...

  • [T细胞向肿瘤细胞内侵润] 免疫循环与介入治疗:T淋巴细胞向肿瘤浸润 日期:2021-01-30 15:57:10 点击:134 好评:0

    RFA (or TACE) + Anti-CTLA4 Checkpoint Inhibitor for HCC 12/14 HCV Reduced viral load Reduced AFP,6 week biopsy: CD8 up only if response 57% PFS @ 6 mo heavily pre-treated pts 消融和Anti-CTLA4后远处肿瘤的镜下表现 Baseline Immune infiltrate...

  • [肿瘤介入与免疫] 文献复习 日期:2020-02-29 23:18:21 点击:116 好评:0

    Curr Opin Gastroenterol 2020 Feb 25[Online ahead of print] New Systemic Agents for Hepatocellular Carcinoma: An Update 2020 Johann von Felden 1 Affiliations expand PMID: 32101985 DOI: 10.1097/MOG.0000000000000626 Abstract Purpose of review...

  • 19条记录